Transplantation or Alternative Surgical Treatment of Patients with Ischemic Dilative Cardiomyopathy and Aneurysmatic Dilation of the Left Ventricular Cavity

Mitrev, Zan; Anguseva, Tanja; Васильева, А. А.; Hristov, Nikola; Risteski, Petar

doi:10.1177/039139880202500411

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All implantations of permanent MCS devices, including left VAD (LVAD) and biventricular VAD (BiVAD), performed at the Department of Cardiovascular Surgery, University St. Cyril and Methodius, and the Department of Cardiovascular Surgery, Zan Mitrev Clinic (both in Skopje) are included in this observation. Before November 2018, there was no dedicated program on a national level for patients with advanced HF, including heart transplantation, and patients have received optimal medical or conventional surgical therapy [Mitrev 2002].…”

Section: Methodsmentioning

confidence: 99%

Outcomes with Ventricular Assist Device Therapy for Advanced Heart Failure in North Macedonia: First Annual Report

Risteski

Anguseva

Rosalia

et al. 2020

HSF

View full text Add to dashboard Cite

Introduction: Mechanical circulatory support by a continuous-flow ventricular assist device (VAD) improves survival and quality of life in selected patients with advanced heart failure. Developing countries have been struggling to construct a contemporary and effective health care system to manage advanced heart failure. This observation represents the first annual report on clinical outcomes with VAD for patients with advanced heart failure in the Republic of North Macedonia. Methods: Data from all patients with VAD implantations between November 2018 and December 2019 were collected. The etiology of the heart failure was dilated cardiomyopathy in 4 patients (57%), ischemic cardiomyopathy in 2 (28%), and hypertrophic cardiomyopathy in 1 (14%). The primary outcome was survival; secondary outcomes included adverse events defined according to the Interagency Registry for Mechanically Assisted Circulatory Support. Results: A total of 7 patients (85% males, median age 56 years) received a VAD; 5 of them received left VAD, and the remaining 2 received biventricular VAD. There were no deaths. Observed morbidity during a mean follow-up of 216 days included 3 bleeding events in 1 patient, 2 patients with superficial driveline infection, and 1 minor stroke and a pump thrombosis, which were treated with VAD exchange. Significant improvement in quality of life, as assessed by the Kansas City Cardiomyopathy Questionnaire and the Functional Independence Measure™ instrument, was seen with all patients. Conclusions: Our results demonstrate a successful initiation of the VAD program in the Republic of North Macedonia. Proper training of a dedicated HF team supports the reproducibility of this treatment in developing countries.

show abstract

Section: Methodsmentioning

confidence: 99%